A new study finds that among patients with wet AMD those with higher risk genotypes response better to Lucentis (ranibizumab) therapy than patients with lower risk genotypes. Epidemiological and association studies have shown that both genetic and environmental factors play a major role in the development of AMD. Association studies have...

Age-related macular degeneration (AMD) has a complex etiology arising from genetic and environmental influences. This past decade have seen several genes associated with the disease. Variants in five genes have been confirmed to play a major role. It is hoped that such research will define the genetic biomarker spectrum to allow treatment...

Genentech and Regeneron Pharmaceuticals have agreed to a partial settlement with regard to ophthalmic sales of aflibercept injections in the United States, according to a press release. Under the plan, Regeneron will receive a non-exclusive license to certain patents for VEGF receptor proteins as well as to other technology patents, the release...

The long-awaited primary outcome of the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) study was that patients receiving either monthly Avastin (bevacizumab) or monthly Lucentis (ranibizumab) had equivalent visual acuity at 1 year. For the majority of clinicians who already preferentially used Avastin for age-related...

The much anticipated CATT study has now been published. The National Eye Institute is to be applauded for having sponsored this landmark trial and for setting a new standard of transparency by submitting most of the raw data on the Internet. Millions of people who cannot afford Lucentis (ranibizumab) now have the benefit of a high level of...

For 5 years, patients and clinicians have wrestled with the choice between two drugs for the treatment of neovascular age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF), the cytokine primarily responsible for blood-vessel growth, is inhibited when anti-VEGF drugs are injected repeatedly into the eye, and blindness is...

Elevated intraocular pressure (IOP) after an intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents for age-related macular degeneration (AMD) is not uncommon, but this study failed to identify any significant risk factors for its occurrence. Studies investigating transient increases in intraocular pressure (IOP)...

Neovascular age-related macular degeneration (AMD) patients undergoing unilateral intravitreal Lucentis (ranibizumab) and/or Avastin (bevacizumab) injections are more likely to suffer intraocular pressure (IOP) elevation of at least 5 mmHg of 2 or more visits if they recieve a greater number of injections, according to a new study. Intravitreal...

Avastin and Lucentis had equivalent effects on visual acuity at 1 year, accirding to the much anticipated Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) research group. Clinical trials have established the efficacy of Lucentis (ranibizumab) for the treatment of neovascular age-related macular degeneration (AMD). In...

Avastin (bevacizumab) is the most popular pharmacological treatment for neovascular age-related macular degeneration (AMD) among Medicare fee-for-service beneficiaries in the United States. Over the past 3 years, both Avastin (bevacizumab) and Lucentis (ranibizumab) have emerged as the most common therapies for neovascular AMD as reported by...